Cost-effectiveness of ribociclib versus palbociclib in combination with an aromatase inhibitor as first-line treatment of postmenopausal women with HR+/HER2− advanced breast cancer: analysis based on final OS results of MONALEESA-2 and PALOMA-2

References

• World Health Organization. Breast cancer. 2021. https://www.who.int/news-room/fact-sheets/detail/breast-cancer
   Google Scholar
• Cancer Research UK. Breast cancer incidence (invasive) statistics. 2021. https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/breast-cancer/incidence-invasive
   Google Scholar
• O'Shaughnessy J. Extending survival with chemotherapy in metastatic breast cancer. Oncologist. 2005;10(S3):20–29.
   PubMedGoogle Scholar
• Metastatic Breast Cancer Network. Incidence and incidence rates. 2022. http://mbcn.org/incidence-and-incidence-rates/
   Google Scholar
• DeKoven M, Bonthapally V, Jiao X, et al. Treatment pattern by hormone receptors and HER2 status in patients with metastatic breast cancer in the UK, Germany, France, Spain and Italy (EU-5): results from a physician survey. J Comp Eff Res. 2012;1(5):453–463.
   PubMed Web of Science ®Google Scholar
• Howlader N, Altekruse SF, Li CI, et al. US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status. J Natl Cancer Inst. 2014;106(5):dju055.
   PubMedGoogle Scholar
• NCI. Surveillance, epidemiology, and end results program. cancer stat facts: female breast cancer subtypes. 2023. https://seer.cancer.gov/statfacts/html/breast-subtypes.html
   Google Scholar
• Elfgen C, Bjelic-Radisic V. Targeted therapy in HR + HER2- Metastatic breast cancer: current clinical trials and their implications for CDK4/6 inhibitor therapy and beyond treatment options. Cancers. 2021;13(23):5994.
   PubMed Web of Science ®Google Scholar
• Spring LM, Wander SA, Zangardi M, et al. CDK 4/6 inhibitors in breast cancer: current controversies and future directions. Curr Oncol Rep. 2019;21(3):25.
   PubMed Web of Science ®Google Scholar
• Finn RS, Boer K, Bondarenko I, et al. Overall survival results from the randomized phase 2 study of palbociclib in combination with letrozole versus letrozole alone for first-line treatment of ER+/HER2- advanced breast cancer (PALOMA-1, TRIO-18). Breast Cancer Res Treat. 2020;183(2):419–428.
   PubMed Web of Science ®Google Scholar
• Finn RS, Crown JP, Lang I, et al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. Lancet Oncol. 2015;16(1):25–35.
   PubMed Web of Science ®Google Scholar
• Finn RS, Martin M, Rugo HS, et al. Palbociclib and letrozole in advanced breast cancer. N Engl J Med. 2016;375(20):1925–1936.
   PubMed Web of Science ®Google Scholar
• Hortobagyi GN, Stemmer S, Burris HA, et al. LBA17 overall survival (OS) results from the phase III MONALEESA-2 (ML-2) trial of postmenopausal patients (pts) with hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2−) advanced breast cancer (ABC) treated with endocrine therapy (ET) ± ribociclib (RIB). Ann Oncol. 2021;32: s1290–S1291.
   Web of Science ®Google Scholar
• Hortobagyi GN, Stemmer SM, Burris HA, et al. Ribociclib as First-Line therapy for HR-Positive, advanced breast cancer. N Engl J Med. 2016;375(18):1738–1748.
   PubMed Web of Science ®Google Scholar
• Xu B, Hu X, Li W, et al. 228MO PALOMA-4: primary results from a phase III trial of palbociclib (PAL) + letrozole (LET) vs placebo (PBO) + LET in asian postmenopausal women with estrogen receptor-positive/human epidermal growth factor receptor 2-negative (ER+/HER2-) advanced breast cancer (ABC). Ann Oncol. 2021;32:s457.
   Web of Science ®Google Scholar
• European Medicines Agency (EMA). Kisqali: summary of Product Characteristics. 2022. https://www.ema.europa.eu/en/documents/product-information/kisqali-epar-product-information_en.pdf
   Google Scholar
• European Medicines Agency (EMA). Ibrance: summary of Product Characteristics. 2022. https://www.ema.europa.eu/en/documents/product-information/ibrance-epar-product-information_en.pdf
   Google Scholar
• Slamon DJ, Neven P, Chia S, et al. Overall survival with ribociclib plus fulvestrant in advanced breast cancer. N Engl J Med. 2020;382(6):514–524.
   PubMed Web of Science ®Google Scholar
• Turner NC, Slamon DJ, Ro J, et al. Overall survival with palbociclib and fulvestrant in advanced breast cancer. N Engl J Med. 2018;379(20):1926–1936.
   PubMed Web of Science ®Google Scholar
• Suri G, Chandiwana D, Lee A, et al. Cost-effectiveness analysis of ribociclib plus letrozole versus palbociclib plus letrozole in the United Kingdom. J Health Econ Outcomes Res. 2019;6(2):20–31.
   PubMedGoogle Scholar
• European Medicines Agency (EMA). Verzenios: summary of Product Characteristics. 2022. https://www.ema.europa.eu/en/documents/product-information/verzenios-epar-product-information_en.pdf
   Google Scholar
• Cameron D, Sharma V, Biswas C, et al. EE361 Cost-Effectiveness analysis of ribociclib Versus abemaciclib in the First-Line (1L) treatment of postmenopausal women With HR+/HER2- Advanced breast cancer (ABC). Value in Health. 2022;25(12S): s126.
   Google Scholar
• Study of Efficacy and Safety of LEE011 in postmenopausal women with advanced breast cancer (MONALEESA-2). 2022. https://clinicaltrials.gov/ct2/show/NCT01958021.
   Google Scholar
• Hortobagyi GN, Stemmer SM, Burris HA, et al. Overall survival with ribociclib plus letrozole in advanced breast cancer. N Engl J Med. 2022;386(10):942–950.
   PubMed Web of Science ®Google Scholar
• Hortobagyi GN, Stemmer SM, Burris HA, et al. Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer. Ann Oncol. 2018;29(7):1541–1547.
   PubMed Web of Science ®Google Scholar
• Study of letrozole with or without palbociclib (PD-0332991) for the first-line treatment of hormone-receptor positive advanced breast cancer. 2022. https://clinicaltrials.gov/ct2/show/NCT00721409
   Google Scholar
• A study of palbociclib (PD-0332991) + Letrozole vs. Letrozole for 1st line treatment of postmenopausal women with ER+/HER2- advanced breast cancer (PALOMA-2). 2022. https://clinicaltrials.gov/ct2/show/NCT01740427
   Google Scholar
• A Study Of Palbociclib (PD-0332991) + Letrozole VS. Placebo + Letrozole for 1st line treatment of asian postmenopausal women with ER+/HER2- advanced breast cancer [PALOMA-4]. 2022. https://clinicaltrials.gov/ct2/show/NCT02297438
   Google Scholar
• Finn RS, Rugo HS, Dieras VC, et al. Overall survival (OS) with first-line palbociclib plus letrozole (PAL + LET) versus placebo plus letrozole (PBO + LET) in women with estrogen receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer (ER+/HER2− ABC): analyses from PALOMA-2. J Clin Oncol. 40(17_suppl):LBA1003–LBA1003.
   Web of Science ®Google Scholar
• Jhaveri K, O'Shaughnessy J, Fasching PA, et al. Matching adjusted indirect comparison of PFS & OS comparing ribociclib + letrozole vs palbociclib + letrozole as first-line treatment of HR+/HER2− ABC: analysis based on updated PFS & final OS results of MONALEESA-2 & PALOMA-2. Eur J Cancer. 2022;175:S2–S3.
   Web of Science ®Google Scholar
• Latimer NR. Survival analysis For economic evaluations alongside clinical Trials - Extrapolation with Patient-Level data. NICE DSU technical support document 14. London: national Institute for Health and Care Excellence (NICE); 2013. https://www.ncbi.nlm.nih.gov/books/NBK395885/
   Google Scholar
• Rugo HS, Finn RS, Diéras V, et al. Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up. Breast Cancer Res Treat. 2019;174(3):719–729.
   PubMed Web of Science ®Google Scholar
• Devlin NJ, Shah KK, Feng Y, et al. Valuing health-related quality of life: an EQ-5D-5L value set for England. Health Econ. 2018;27(1):7–22.
   PubMed Web of Science ®Google Scholar
• Hudgens S, Briggs A, Tremblay G, et al. Comparison of methods to estimate health state utilities in metastatic breast cancer (MBC). Value Health. 2014;17(7):A557.
   PubMed Web of Science ®Google Scholar
• Lloyd A, Nafees B, Narewska J, et al. Health state utilities for metastatic breast cancer. Br J Cancer. 2006;95(6):683–690.
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence. British National Formulary (BNF). 2022. https://bnf.nice.org.uk/
   Google Scholar
• National Health Service. 2019-20 reference costs. 2022. https://digital.nhs.uk/data-and-information/data-collections-and-data-sets/data-collections/reference-costs
   Google Scholar
• Brufsky AM. Delaying chemotherapy in the treatment of hormone Receptor-Positive, human epidermal growth factor receptor 2-Negative advanced breast cancer. Clin Med Insights Oncol. 2015;9:137–147.
   PubMed Web of Science ®Google Scholar
• Das R, Cope S, Ouwens M, et al. Economic evaluation of fulvestrant 500 mg versus generic nonsteroidal aromatase inhibitors in patients with advanced breast cancer in the United Kingdom. Clin Ther. 2013;35(3):246–260.e5.
   PubMed Web of Science ®Google Scholar
• Lin PL, Hao Y, Xie J, et al. Physician experiences and preferences in the treatment of HR+/HER2- metastatic breast cancer in the United States: a physician survey. Cancer Med. 2016;5(2):209–220.
   PubMed Web of Science ®Google Scholar
• Macalalad AR, Hao Y, Lin PL, et al. Treatment patterns and duration in post-menopausal women with HR+/HER2- metastatic breast cancer in the US: a retrospective chart review in community oncology practices (2004-2010). Curr Med Res Opin. 2015;31(2):263–273.
   PubMed Web of Science ®Google Scholar
• Saad ED, Katz A, Buyse M. Overall survival and post-progression survival in advanced breast cancer: a review of recent randomized clinical trials. J Clin Oncol. 2010;28(11):1958–1962.
   PubMed Web of Science ®Google Scholar
• Round J, Jones L, Morris S. Estimating the cost of caring for people with cancer at the end of life: a modelling study. Palliat Med. 2015;29(10):899–907.
   PubMed Web of Science ®Google Scholar
• Signorovitch JE, Sikirica V, Erder MH, et al. Matching-adjusted indirect comparisons: a new tool for timely comparative effectiveness research. Value Health. 2012;15(6):940–947.
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence. Abemaciclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer [TA563]. 2019. https://www.nice.org.uk/guidance/ta563
   Google Scholar